Literature DB >> 1750639

CPAP, effective respiratory support in patients with AIDS-related Pneumocystis carinii pneumonia.

H P Prevedoros1, R P Lee, D Marriot.   

Abstract

Human Immunodeficiency Virus (HIV) related Pneumocystis carinii pneumonia (PCP) associated with severe respiratory failure is an increasingly common problem in major centres and is associated with a high mortality in previous and recent studies. Early in the epidemic, alternatives to invasive intensive care treatment were utilized in our institution and found to be successful. When respiratory failure developed, mask CPAP was used instead of intubation and ventilation. A retrospective review of 175 cases of HIV infected patients with confirmed first presentation PCP was undertaken. Treatment with our protocol resulted in an overall hospital mortality of 9%. Those patients who did not require supplemental oxygen or respiratory support had no in-hospital mortality. The group who required supplemental oxygen had a mortality of 10%. If respiratory failure supervened (severe respiratory distress, PaO2 less than 50 mmHg, SaO2 less than 90% on mask oxygen), CPAP was introduced. The mortality in this group was 22%. Only two patients were admitted to the intensive care unit for respiratory support after failure of CPAP. Both patients were intubated and received intermittent positive pressure ventilation (IPPV). Both patients died.

Entities:  

Mesh:

Year:  1991        PMID: 1750639     DOI: 10.1177/0310057X9101900413

Source DB:  PubMed          Journal:  Anaesth Intensive Care        ISSN: 0310-057X            Impact factor:   1.669


  3 in total

1.  Non-invasive ventilation in acute respiratory failure.

Authors: 
Journal:  Thorax       Date:  2002-03       Impact factor: 9.139

Review 2.  Neonatal pneumonia in developing countries.

Authors:  T Duke
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2005-05       Impact factor: 5.747

Review 3.  The use of non-invasive ventilation during acute respiratory failure due to pneumonia.

Authors:  Miquel Ferrer; Roberto Cosentini; Stefano Nava
Journal:  Eur J Intern Med       Date:  2012-03-28       Impact factor: 4.487

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.